Author correction to “A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease” [Acta Pharmaceutica Sinica B 12, (2021) 4032–4044]

Surface-decorated nanoliposomal leonurine targets activated fibroblast-like synoviocytes for efficient rheumatoid arthritis therapy

“…S1a and b, † the decrease of the single peak at δ = 7.0 ppm derived from the double bonds in MAL and the appearance of multiple peaks at δ = 6.7-6.9 ppm from the peptide revealed the successful synthesis of DSPE-PEG-MAL-HAP. 22 Afterward, DSPE-PEG 5000 -HAP and DSPE-PEG 2000 -mPEG were inserted into lipid bilayers of Lipo through hydrophobic interactions to generate FLS-targeting and long-circulating liposomes (HAP-Lipo). Varying the molar ratios of DSPE-PEG 5000 -HAP to DSPE-mPEG 2000 resulted in slight changes in the particle size (Fig.…”

“…More specifically, the liposome was loaded with Leo and decorated with two different lengths of DSPE-PEGs, the longer one (DSPE-PEG 5000 -MAL) for conjugating HAP-1, an FLS-targeting peptide, while the shorter one DSPE-mPEG 2000 for long-circulation in vivo. 22 Under the guidance of HAP-1, HAP-Lipo@Leo specifically targets FLS and allows for sustained release of Leo for superior therapeutic efficacy against RA. The in vitro and in vivo investigations confirmed the targetability, safety, antiinflammatory, synovial protective, and anti-erosion capabilities of HAP-Lipo@Leo.…”